BACKGROUND: Radiotherapy may synergize with programmed cell death 1 (PD1)/PD1 ligand (PD-L1) blockade. The purpose of this study was to determine the recommended phase II dose, safety/tolerability, and preliminary efficacy of combining pembrolizumab, an anti-PD1 monoclonal antibody, with hypofractionated stereotactic irradiation (HFSRT) and bevacizumab in patients with recurrent high-grade gliomas (HGGs). METHODS: Eligible subjects with recurrent glioblastoma or anaplastic astrocytoma were treated with pembrolizumab (100 or 200 mg based on dose level Q3W) concurrently with HFSRT (30 Gy in 5 fractions) and bevacizumab 10 mg/kg Q2W. RESULTS: Thirty-two patients were enrolled (bevacizumab-naïve, n = 24; bevacizumab-resistant, n = 8). The most common treatment-related adverse events (TRAEs) were proteinuria (40.6%), fatigue (25%), increased alanine aminotransferase (25%), and hypertension (25%). TRAEs leading to discontinuation occurred in 1 patient who experienced a grade 3 elevation of aspartate aminotransferase. In the bevacizumab-naïve cohort, 20 patients (83%) had a complete response or partial response. The median overall survival (OS) and progression-free survival (PFS) were 13.45 months (95% CI: 9.46-18.46) and 7.92 months (95% CI: 6.31-12.45), respectively. In the bevacizumab-resistant cohort, PR was achieved in 5 patients (62%). Median OS was 9.3 months (95% CI: 8.97-18.86) with a median PFS of 6.54 months (95% CI: 5.95-18.86). The majority of patients (n = 20/26; 77%) had tumor-cell/tumor-microenvironment PD-L1 expression <1%. CONCLUSIONS: The combination of HFSRT with pembrolizumab and bevacizumab in patients with recurrent HGG is generally safe and well tolerated. These findings merit further investigation of HFSRT with immunotherapy in HGGs.
BACKGROUND: Radiotherapy may synergize with programmed cell death 1 (PD1)/PD1 ligand (PD-L1) blockade. The purpose of this study was to determine the recommended phase II dose, safety/tolerability, and preliminary efficacy of combining pembrolizumab, an anti-PD1 monoclonal antibody, with hypofractionated stereotactic irradiation (HFSRT) and bevacizumab in patients with recurrent high-grade gliomas (HGGs). METHODS: Eligible subjects with recurrent glioblastoma or anaplastic astrocytoma were treated with pembrolizumab (100 or 200 mg based on dose level Q3W) concurrently with HFSRT (30 Gy in 5 fractions) and bevacizumab 10 mg/kg Q2W. RESULTS: Thirty-two patients were enrolled (bevacizumab-naïve, n = 24; bevacizumab-resistant, n = 8). The most common treatment-related adverse events (TRAEs) were proteinuria (40.6%), fatigue (25%), increased alanine aminotransferase (25%), and hypertension (25%). TRAEs leading to discontinuation occurred in 1 patient who experienced a grade 3 elevation of aspartate aminotransferase. In the bevacizumab-naïve cohort, 20 patients (83%) had a complete response or partial response. The median overall survival (OS) and progression-free survival (PFS) were 13.45 months (95% CI: 9.46-18.46) and 7.92 months (95% CI: 6.31-12.45), respectively. In the bevacizumab-resistant cohort, PR was achieved in 5 patients (62%). Median OS was 9.3 months (95% CI: 8.97-18.86) with a median PFS of 6.54 months (95% CI: 5.95-18.86). The majority of patients (n = 20/26; 77%) had tumor-cell/tumor-microenvironment PD-L1 expression <1%. CONCLUSIONS: The combination of HFSRT with pembrolizumab and bevacizumab in patients with recurrent HGG is generally safe and well tolerated. These findings merit further investigation of HFSRT with immunotherapy in HGGs.
Authors: Jason J Luke; Jeffrey M Lemons; Theodore G Karrison; Sean P Pitroda; James M Melotek; Yuanyuan Zha; Hania A Al-Hallaq; Ainhoa Arina; Nikolai N Khodarev; Linda Janisch; Paul Chang; Jyoti D Patel; Gini F Fleming; John Moroney; Manish R Sharma; Julia R White; Mark J Ratain; Thomas F Gajewski; Ralph R Weichselbaum; Steven J Chmura Journal: J Clin Oncol Date: 2018-02-13 Impact factor: 44.544
Authors: Betty Li; Alshad S Lalani; Thomas C Harding; Bo Luan; Kathryn Koprivnikar; Guang Huan Tu; Rodney Prell; Melinda J VanRoey; Andrew D Simmons; Karin Jooss Journal: Clin Cancer Res Date: 2006-11-15 Impact factor: 12.531
Authors: Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen Journal: Cancer Res Date: 2009-03-10 Impact factor: 12.701
Authors: M Zahidunnabi Dewan; Ashley E Galloway; Noriko Kawashima; J Keith Dewyngaert; James S Babb; Silvia C Formenti; Sandra Demaria Journal: Clin Cancer Res Date: 2009-08-25 Impact factor: 12.531
Authors: Magali Terme; Simon Pernot; Elie Marcheteau; Federico Sandoval; Nadine Benhamouda; Orianne Colussi; Olivier Dubreuil; Antoine F Carpentier; Eric Tartour; Julien Taieb Journal: Cancer Res Date: 2012-10-29 Impact factor: 12.701
Authors: Antonio Omuro; Gordana Vlahovic; Michael Lim; Solmaz Sahebjam; Joachim Baehring; Timothy Cloughesy; Alfredo Voloschin; Shakti H Ramkissoon; Keith L Ligon; Robert Latek; Ricardo Zwirtes; Lewis Strauss; Prashni Paliwal; Christopher T Harbison; David A Reardon; John H Sampson Journal: Neuro Oncol Date: 2018-04-09 Impact factor: 12.300
Authors: Hideho Okada; Michael Weller; Raymond Huang; Gaetano Finocchiaro; Mark R Gilbert; Wolfgang Wick; Benjamin M Ellingson; Naoya Hashimoto; Ian F Pollack; Alba A Brandes; Enrico Franceschi; Christel Herold-Mende; Lakshmi Nayak; Ashok Panigrahy; Whitney B Pope; Robert Prins; John H Sampson; Patrick Y Wen; David A Reardon Journal: Lancet Oncol Date: 2015-11 Impact factor: 41.316
Authors: David A Reardon; Alba A Brandes; Antonio Omuro; Paul Mulholland; Michael Lim; Antje Wick; Joachim Baehring; Manmeet S Ahluwalia; Patrick Roth; Oliver Bähr; Surasak Phuphanich; Juan Manuel Sepulveda; Paul De Souza; Solmaz Sahebjam; Michael Carleton; Kay Tatsuoka; Corina Taitt; Ricardo Zwirtes; John Sampson; Michael Weller Journal: JAMA Oncol Date: 2020-07-01 Impact factor: 31.777
Authors: Santiago Cabezas-Camarero; Rebeca Pérez-Alfayate; Vanesa García-Barberán; María Carmen Polidura; María Natividad Gómez-Ruiz; Isabel Casado-Fariñas; Issa Ahmad Subhi-Issa; José Carlos Plaza Hernández; Pilar Garre; Isabel Díaz-Millán; Pedro Pérez-Segura Journal: Ther Adv Med Oncol Date: 2022-06-08 Impact factor: 5.485